The pressure is on hospitals to set pricing strategies that are competitive without risking revenue. Learn how revenue integrity professionals can help their organizations take a pricing approach that's truly strategic.Read More »
The April 2019 OPPS quarterly update reassigned specific skin substitute products from the low-cost group to the high-cost group, and clarified billing and reporting for chimeric antigen receptor T-cell (CAR-T) therapy procedures performed in the outpatient setting.Read More »
CMS is seeking comments on a proposed coverage with evidence development for chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory cancer when prescribed by the treating oncologist.Read More »
